Medical Cannabis for Chronic Pain: What the Evidence Supports, and What It Doesn’t

Medical cannabis is widely discussed as an option for chronic pain, but the evidence is more limited—and more nuanced—than many product claims suggest. For some people, cannabis-based medicines may provide modest short-term relief, particularly for certain neuropathic pain conditions. They can also cause dizziness, drowsiness, nausea, impaired attention, and cognitive effects.

Chronic pain can arise from an injury, inflammation, an underlying disease, nerve damage, medical treatment, or no identifiable cause. Because its causes and effects vary, treatment usually combines several approaches, such as physical rehabilitation, psychological support, non-opioid medicines, and, when appropriate, prescription opioids. Cannabis should be considered only as part of an individualized plan—not as a universal replacement for established care.

What the research shows

A 2021 systematic review and meta-analysis published in The BMJ evaluated 32 randomized trials involving 5,174 adults with chronic cancer-related or non-cancer pain. Most studies examined oral cannabis-based medicines rather than smoked or vaporized cannabis. Compared with placebo, non-inhaled products produced small improvements in pain relief, physical functioning, and sleep quality. The studies generally followed participants for only one to five and a half months, so they provide limited information about long-term effectiveness and safety.

The size of the average benefit matters. The review found that cannabis-based medicines increased the proportion of people achieving meaningful pain relief by about 10 percentage points compared with placebo. That suggests some patients may benefit, but many will not—and the improvement is unlikely to be dramatic for most people.

The National Center for Complementary and Integrative Health similarly describes the evidence as showing modest benefits at best. Research is strongest for some forms of neuropathic pain, which results from damage or dysfunction in the nerves. Evidence for other chronic pain conditions remains inconsistent, and studies have not established that cannabis works better than conventional treatments.

THC, CBD, and other cannabinoids

Cannabis contains many biologically active compounds. The two best known are tetrahydrocannabinol, or THC, and cannabidiol, or CBD.

• THC is the compound primarily responsible for intoxication. It may contribute to pain relief, but it can also cause impaired attention, dizziness, anxiety, sleepiness, and problems with memory or coordination.
• CBD does not produce the same intoxicating “high” as THC. However, a lack of intoxication does not mean a product is risk-free. CBD can cause gastrointestinal symptoms, sleepiness, liver-related problems, and interactions with other medicines.

Other compounds, including CBG, CBN, THCA, and cannabis terpenes, are being investigated. Their potential effects are not yet well established in clinical research, and laboratory findings should not be treated as proof that a particular product will relieve pain in people.

Delivery method affects the treatment experience

Cannabis products differ substantially in how quickly they act, how long their effects last, and how reliably a dose can be measured.

• Oral products, such as capsules, oils, and edibles, may last longer but can take much longer to produce an effect. This delay can increase the risk of taking too much.
• Sublingual products placed under the tongue may act sooner than products that must pass through the digestive system, although absorption still varies.
• Topical products are marketed for localized symptoms. Their ability to relieve deeper or widespread chronic pain is less certain.
• Smoking and vaporizing produce faster effects but expose users to inhaled substances and make precise dosing difficult. The BMJ review did not establish whether inhaled cannabis provides the same benefits as the oral products studied in its trials.

Product labels may not accurately reflect the amount of THC or CBD present, particularly outside tightly regulated prescription medicines. The NCCIH notes that some commercial products have contained substantially different cannabinoid concentrations than their labels indicated, along with contaminants such as pesticides or microorganisms.

Safety and practical considerations

Anyone considering cannabis for chronic pain should first discuss it with a healthcare professional who knows their medical history and current medications. Cannabis may interact with prescription drugs, alcohol, and other sedating substances. Combining cannabis with alcohol can increase impairment, while using cannabis alongside opioids may increase risks related to misuse and adverse effects. Cannabis is not an established treatment for opioid use disorder.

People should be especially cautious if they have a history of substance use disorder, psychosis, significant cardiovascular disease, liver disease, or medication-related sedation. Cannabis can also impair driving and other activities that require alertness or coordination. Pregnant or breastfeeding individuals should consult a healthcare professional before using cannabis or CBD products.

Legal access and product rules vary by jurisdiction. In the United States, state medical-cannabis programs do not mean that the cannabis plant itself has been approved by the U.S. Food and Drug Administration. The FDA has approved specific cannabinoid-related prescription medicines for particular conditions, but not cannabis as a general treatment for chronic pain.

A role within comprehensive pain care

If a clinician and patient decide to try a cannabis-based medicine, the plan should define a specific goal—such as improved sleep, greater activity, or a measurable reduction in pain—along with a time frame for reassessment. Starting with a low dose and increasing gradually may reduce adverse effects, but dosing advice must be individualized because products and patient responses vary.

Cannabis should not displace treatments that are helping. Exercise prescribed for the relevant condition, physical or occupational therapy, cognitive behavioral therapy, mindfulness-based approaches, sleep treatment, and management of depression or anxiety can all play important roles in chronic pain care. The NCCIH overview of chronic pain and complementary approaches provides additional evidence-based context on these options.

Overall, medical cannabis may offer modest short-term relief for some adults with chronic pain, but it is not a proven solution for every pain condition. The best-supported approach is cautious, supervised, and outcome-focused: weigh the potential benefits against impairment, side effects, drug interactions, cost, and the uncertainty surrounding long-term use.